Sepsis News and Research

Latest Sepsis News and Research

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Schizophrenia patients likely to sustain medical injuries during non-psychiatric hospital stay

People with schizophrenia are more likely than others to sustain medical injuries during non-psychiatric hospital stays, a large national study finds.These findings confirm that medical and surgical hospitalizations are an at-risk time for this group, and a national problem, said lead study author Elizabeth Khaykin, at the Department of Mental Health at Bloomberg Johns Hopkins School of Public Health.

23 Jul 2010

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

New research from The Methodist Hospital in Houston shows that sepsis is 10 times more common and more lethal than other more well-known surgical complications including heart attacks and blood clots. These results, published today in the Archives of General Surgery, show a greater need for sepsis awareness and early recognition during and after surgery.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.

19 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

Biggest breasted woman seriously ill after breast augmentation surgery

Brazilian model Sheyla Hershey, 30 apparently with the largest breasts in the world is seriously ill with complications following her latest breast augmentation surgery. Ms Hershey who lives in Houston, Texas contracted a severe staphylococcal infection after her surgery in June.

13 Jul 2010

Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards announced

URAC announced today that a distinguished panel of judges has selected 30 finalists for its Best Practices in Health Care Consumer Empowerment and Protection Awards. The competition drew entries from across the nation. The finalists will be honored during URAC's 11th Annual Quality Summit, October 5-7, 2010 in Chicago, IL. The awards honor programs in two areas: Consumer Decision-Making and Consumer Health Improvement.

13 Jul 2010

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

Cumberland Pharmaceuticals Inc. today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene. The study, which is the first to document an antipyretic effect of an injectable non-steroidal anti-inflammatory drug on fever caused by malaria, demonstrated that patients who received intravenous ibuprofen experienced a greater reduction in their temperatures than those who received placebo.

13 Jul 2010

European Commission approves new indication for ORENCIA in combination with MTX for RA

Bristol-Myers Squibb Company has today announced that on 1 July 2010 the European Commission approved a new indication for ORENCIA® (abatacept), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a TNF-alpha inhibitor.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

A new study from researchers in Ottawa and Toronto suggests that a commonly used type of bone marrow stem cell may be able to help treat sepsis, a deadly condition that can occur when an infection spreads throughout the body. The study, published in the American Journal of Respiratory and Critical Care Medicine, shows that these cells can triple survival rates in an experimental model of sepsis.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Gold Standard Diagnostics, Inc. a leading supplier of products and services to the medical diagnostic industry today announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the U.S. Market. Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, sepsis. GSD will initially focus on distribution of Homocysteine, but also gains access to distribute Axis-Shield's other key products such as Anti-CCP.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Infection and severe sepsis mortality rates higher in black patients

A greater frequency of severe sepsis among black patients is attributable to higher rates of infection and higher risks of organ dysfunction than what white patients experience, according to a study in the June 23/30 issue of JAMA.

30 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

The quality of emergency medical care at the nation's hospitals varies widely - both individually and by state - according to a new HealthGrades study released today that, for the first time, examines mortality rates for patients entering hospitals through emergency departments.

23 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

Sepsis News and Research

Latest Sepsis News and Research

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Schizophrenia patients likely to sustain medical injuries during non-psychiatric hospital stay

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

MD Buyline identifies top emerging technologies with highest impact

Biggest breasted woman seriously ill after breast augmentation surgery

Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards announced

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

European Commission approves new indication for ORENCIA in combination with MTX for RA

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Infection and severe sepsis mortality rates higher in black patients

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sepsis News and Research

Latest Sepsis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in